Stockscreener 앱 받기
6.513
3.06%
-0.197
전일 마감가:
$6.71
열려 있는:
$6.72
하루 거래량:
43,549
Relative Volume:
0.26
시가총액:
$370.73M
수익:
-
순이익/손실:
$-66.86M
주가수익비율:
-5.4275
EPS:
-1.2
순현금흐름:
$-58.82M
1주 성능:
-8.64%
1개월 성능:
+11.20%
6개월 성능:
+92.46%
1년 성능:
+15.13%
1일 변동 폭
$6.43
$7.21
1주일 범위
$6.00
$7.21
52주 변동 폭
$2.60
$7.77
디자인 테라 Stock (DSGN) Company Profile
명칭
Design Therapeutics Inc
전화
858-293-4900
주소
6005 HIDDEN VALLEY ROAD, CARLSBAD
DSGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DSGN
Design Therapeutics Inc
|
6.51 | 377.00M | 0 | -66.86M | -58.82M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.63 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
485.30 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.62 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
831.23 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.36 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
디자인 테라 Stock (DSGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-07 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-11-14 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-08-15 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-15 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2023-08-15 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-05-04 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-06-10 | 개시 | Wedbush | Outperform |
| 2022-05-02 | 개시 | RBC Capital Mkts | Outperform |
| 2022-01-19 | 개시 | Goldman | Sell |
| 2021-04-20 | 개시 | Goldman | Neutral |
| 2021-04-20 | 개시 | Piper Sandler | Overweight |
| 2021-04-20 | 개시 | SVB Leerink | Outperform |
모두보기
디자인 테라 주식(DSGN)의 최신 뉴스
Developing predictive dashboards with Design Therapeutics Inc. dataJuly 2025 WrapUp & Weekly Setup with ROI Potential - newser.com
How to integrate Design Therapeutics Inc. into portfolio analysis toolsQuarterly Market Summary & Risk Managed Investment Strategies - newser.com
Published on: 2025-10-14 04:26:55 - newser.com
Nabla Bio Signs Second Takeda Collaboration to Advance AI-Driven Design of Protein Therapeutics - Business Wire
How Design Therapeutics Inc. stock reacts to global recession fearsTrade Analysis Summary & Safe Capital Allocation Plans - newser.com
Does Design Therapeutics Inc. fit your quant trading modelIndex Update & Risk Controlled Daily Trade Plans - newser.com
Is it time to cut losses on Design Therapeutics Inc.Analyst Downgrade & Risk Controlled Daily Plans - newser.com
Published on: 2025-10-10 09:52:08 - newser.com
Leading vs lagging indicators on Design Therapeutics Inc. performanceJuly 2025 Intraday Action & Daily Entry Point Alerts - newser.com
Is Design Therapeutics Inc. a candidate for recovery playJuly 2025 EndofMonth & Accurate Entry/Exit Alerts - newser.com
Design Therapeutics Inc. stock volume spike explainedJuly 2025 Short Interest & AI Optimized Trade Strategies - newser.com
Why Design Therapeutics Inc. stock is in analyst buy zone2025 Technical Overview & Low Drawdown Trading Strategies - newser.com
Design Therapeutics (NASDAQ:DSGN) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Published on: 2025-10-09 02:15:05 - newser.com
Resolution Therapeutics to present EMERALD study design at the British Association for the Study of the Liver (BASL) annual meeting 2025 - Yahoo Finance
Fuchs Endothelial Corneal Dystrophy Market Report 2025-2035: Epidemiology, Regulatory Landscape, Ong - PharmiWeb.com
Is Design Therapeutics Inc a good long term investmentInstitutional Buying Trends & Low Entry Investment Plans - earlytimes.in
Fuchs Endothelial Corneal Dystrophy Market Report 2025-2035: Epidemiology, Regulatory Landscape, Ongoing Clinical Trials, Market Dynamics, Patent AnalysisResearchAndMarkets.com - Business Wire
Design Therapeutics Inc. recovery potential after sell offFed Meeting & Real-Time Chart Pattern Alerts - newser.com
Should you hold or exit Design Therapeutics Inc. now2025 Technical Overview & Smart Investment Allocation Tips - newser.com
Top chart patterns to watch in Design Therapeutics Inc.2025 Price Targets & Free Verified High Yield Trade Plans - newser.com
RBC Capital Maintains Design Therapeutics(DSGN.US) With Hold Rating, Maintains Target Price $5 - 富途牛牛
Analyzing Design Therapeutics Inc. with multi timeframe chartsJuly 2025 Big Picture & Smart Allocation Stock Tips - newser.com
Risk adjusted return profile for Design Therapeutics Inc. analyzedEarnings Performance Report & Stepwise Entry and Exit Trade Signals - newser.com
Why Design Therapeutics Inc. stock is a must watch in 2025Trade Signal Summary & Smart Swing Trading Alerts - newser.com
Twist Bioscience Announces Publication in Science Examining Biosecurity Screening Practices in AI-assisted Protein Design - Business Wire
Vector Science & Therapeutics Appoints Tabitha Hendren as Director, Engineering and Design - PR Newswire Canada
Fuchs Endothelial Corneal Dystrophy Market Report 2025-2035: Bausch + Lomb, Santen Pharmaceutical, and Trefoil Therapeutics, Actively Shaping the Competitive Landscape - 24matins.uk
Design Therapeutics Inc Stock Analysis and ForecastStock Rotation Strategies & Low Cost Stock Picks - earlytimes.in
디자인 테라 (DSGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.80%
1.55%
자본화:
|
볼륨(24시간):